News
PHAT
11.05
+5.24%
0.55
ANGI, MLKN and KOD are among after hour movers
On the Move ANGI, MLKN and KOD are among after hour movers. ATHA, XERS, KOD, PHAT, INZY, NAMSW, LENZ are among the day's losers. MillerKnoll is down 13%.
Seeking Alpha · 14h ago
Weekly Report: what happened at PHAT last week (0318-0322)?
Weekly Report · 3d ago
Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by Needham
Dow Jones · 5d ago
Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
Benzinga · 5d ago
Positive Prescription Trends and Resilience Prompt Buy Rating for Phathom Pharmaceuticals
TipRanks · 5d ago
Weekly Report: what happened at PHAT last week (0311-0315)?
Weekly Report · 03/18 09:07
Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion
FDA has set a target action date of July 19, 2024, for expanded approval of Voquenza, which would target the larger Non-Erosive GERD patient population. The global market for GERD therapies is expected to be $3.4 billion by 2032. Phathom Pharmaceuticals is gearing up to potentially receive an expanded FDA approval of its drug for patients with non-erosive gastroesophageal reflux disease. A phase 3 study for this patient population is expected in 2024.
Seeking Alpha · 03/18 05:19
Phathom Pharmaceuticals Is Maintained at Buy by Needham
Dow Jones · 03/15 14:45
Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by Needham
Dow Jones · 03/15 14:45
Needham Maintains Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
Benzinga · 03/15 14:34
Analysts’ Top Healthcare Picks: Longboard Pharmaceuticals (LBPH), Phathom Pharmaceuticals (PHAT)
Analysts maintain Buy ratings on Longboard Pharmaceuticals and Phathom Pharmaceuticals. Longboard has an analyst consensus of Strong Buy, with a price target of $41.88. Needham analyst Joseph Stringer maintained a Buy rating on Phathom. The company's shares closed at $7.93 today.
TipRanks · 03/15 14:30
Weekly Report: what happened at PHAT last week (0304-0308)?
Weekly Report · 03/11 09:06
Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by Needham
Dow Jones · 03/08 19:32
Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
Benzinga · 03/08 19:22
Phathom Pharmaceuticals Price Target Maintained With a $28.00/Share by HC Wainwright & Co.
Dow Jones · 03/08 14:54
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target
Benzinga · 03/08 14:44
Craig-Hallum Issues a Buy Rating on Phathom Pharmaceuticals (PHAT)
Alexander Nowak from Craig-Hallum assigned a Buy rating to Phathom Pharmaceuticals (PHAT – Research Report). The company’s shares closed yesterday at $9.09. The analyst consensus on PHAT is a Strong Buy with an average price target of $22.75. The corporate insider sentiment is negative on the stock.
TipRanks · 03/08 13:46
Phathom Pharmaceuticals’ Voquezna Shows Promising Market Traction and Growth Potential: A Buy Rating Analysis
TipRanks · 03/08 11:27
Maintaining Neutral on Phathom Pharmaceuticals Amid Voquezna Launch Uncertainties
TipRanks · 03/07 22:35
PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023
Phathom Pharmaceuticals reported earnings per share of -$1.39. The company reported revenue of $682,000. This was 66.34% better than the analyst estimate for revenue of  $410,000 . The company's revenue was below the average estimate for the quarter.
Investorplace · 03/07 18:51
More
Webull provides a variety of real-time PHAT stock news. You can receive the latest news about Phathom Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PHAT
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.